Search clinical trials for: Cobicistat

Total 142 results

Fore Biotherapeutics

Not yet recruiting

A Study of the Effects of Food and Cobicistat on Plixorafenib Pharmacokinetics in Healthy Volunteers.

Healthy Volunteer

United States
Gilead Sciences

Not yet recruiting

A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments

HIV-1-infection
Daiichi Sankyo

Recruiting

A Study of Valemetostat in Combination With DXd ADCs in Subjects With Solid Tumors

Advanced Solid Tumor

United States
Henan Cancer Hospital

Not yet recruiting

Disitamab Vedotin Combined With Sintilimab and XELOX Perioperative Treatment for Resectable Gastric Caner With HER2 Overexpression

Gastric Cancer

China
Stichting Hemato-Oncologie voor Volwassenen Nederland

Recruiting

A Trial to Assess Cobicistat Boosted Venetoclax in Combination With Azacitidine in Adult Patients With Newly Diagnosed AML (HO171)

AML, Adult

Netherlands
Maastricht University Medical Center

Recruiting

Improving Osimertinib Exposure and Cost-effectiveness Using Pharmacokinetic Boosting With Cobicistat (OSIBOOST-2)

Non-small Cell Lung Cancer

Netherlands
Fore Biotherapeutics

Recruiting

A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

Cancer Harboring BRAF Alterations

United States, Germany, Spain, United Kingdom, Korea, Republic of, Italy, France, Sweden, Canada
German Cancer Research Center
University Hospital Heidelberg

Recruiting

A Trial of Cobicistat and Gemcitabine and Nab-Paclitaxel in Patients With Advanced Stage or Metastatic Pancreatic Ductal Adenocarcinoma (IntenSify)

Pancreatic Cancer | Pancreatic Adenocarcinoma | CYP3A Inhibitor | Advanced Stage or Metastatic Pancreatic Ductal Adenocarcinoma | Pancreatic Neoplasm

Germany
East Carolina University
Janssen Scientific Affairs, LLC

Recruiting

Effect of Biktarvy & Symtuza on microRNAs in HIV and Correlation With Weight Gain

HIV Infections | Obesity

United States
Radboud University Medical Center

Recruiting

Pharmacokinetic Boosting of Olaparib to Improve Exposure, Tolerance and Cost-effectiveness (PROACTIVE)

Cancer

Netherlands
National Institute of Allergy and Infectious Diseases...
Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaborators

Recruiting

Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum

HIV Infections | Tuberculosis

United States, Malawi, Puerto Rico, South Africa, Thailand, Zimbabwe, Brazil, Kenya, Uganda, India, Tanzania, Botswana
Syndax Pharmaceuticals

Recruiting

A Study of SNDX-5613 in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation (AUGMENT-101)

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Acute Leukemia of Ambiguous Lineage | Mixed Phenotype Acute Leukemia | Mixed Lineage Acute Leukemia

United States, Israel, Spain, Australia, Netherlands, Germany, Canada, France, Italy, Lithuania
Gilead Sciences

Recruiting

Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV

HIV Infections | Acquired Immune Deficiency Syndrome (AIDS)

United States, Thailand, South Africa, Argentina, Panama, Zimbabwe, United Kingdom, Uganda
Asan Medical Center

Recruiting

Impact of Sonifilan on the Quality of Life in Patients With Cervical Cancer During Radiation or Chemoradiation Therapy

Cervical Cancer

Korea, Republic of
University of Zurich

Recruiting

Characterization of Acute and Recent HIV-1 Infections in Zurich: a Long-term Observational Study

HIV Infections

Switzerland
The Crofoot Research Center, Inc.
Janssen Scientific Affairs, LLC

Completed

Rapid Reinitiation of a Single Tablet Antiretroviral Therapy Using Symtuza® in HIV-1 Infected Treatment-Experienced Patients Off Therapy. (ReSTART) (ReSTART)

HIV-1-infection

United States
Gilead Sciences

Active, not recruiting

Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents and Virologically Suppressed Children

HIV Infections | Acquired Immune Deficiency Syndrome (AIDS)

United States, Thailand, Uganda, South Africa, Zimbabwe
IRCCS San Raffaele
Gilead Sciences

Terminated

Switch From Dual Regimens Based on Dolutegravir Plus a Reverse Transcriptase Inhibitor to E/C/F/TAF in Virologically Suppressed, HIV-1 Infected Patients (Be-OnE) (Be-OnE)

HIV-1-infection

Italy
National Institutes of Health Clinical Center (CC)

Completed

Impact of Steady State Cobicistat and Darunavir/Cobicistat on the Pharmacokinetics and Pharmacodynamics of Oral Anticoagulants (Rivaroxaban, Apixaban) in Health Volunteers

Healthy Volunteers

United States
Gilead Sciences

Terminated

Drug-Drug Interaction Study of Vesatolimod in Adults With HIV-1 Who Have Very Low or Undetectable Virus Levels

Human Immunodeficiency Virus Type 1 (HIV-1) Infection

United States
Merck Sharp & Dohme LLC

Completed

Safety and Efficacy of a Switch to Doravirine, Tenofovir, Lamivudine (MK-1439A) in Human Immunodeficiency Virus (HIV-1)-Infected Participants Virologically Suppressed on an Anti-retroviral Regimen in Combination With Two Nucleoside Reverse Transcriptase Inhibitors (MK-1439A-024) (DRIVE-SHIFT)

HIV-1 Infection
Janssen Research & Development, LLC

Completed

A Study to Assess the Acceptability of the Darunavir/Cobicistat (DRV/COBI) Fixed-dose Combination (FDC) Tablet in Human Immunodeficiency Virus (HIV)-1 Infected Children

Human Immunodeficiency Virus (HIV)

United States, Spain, South Africa
Janssen Scientific Affairs, LLC

Completed

A Study of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Evaluated as a Fixed Dose Combination Regimen in Participants Switching From an Integrase Inhibitor Who Have Experienced Rapid Weight Gain (DEFINE)

HIV-1

United States
Augusta University

Completed

Contribution of Dolutegravir to Obesity and Cardiovascular Disease

Vascular Diseases | Body Weight Changes | Cardiovascular Abnormalities | HIV-1-infection | Body Fat Disorder | HIV-Associated Lipodystrophy Syndrome | Antiviral Drug Adverse Reaction | Abnormality of Adipose Tissue

United States
Brigham and Women's Hospital
Johns Hopkins University; National Institute on Aging (NIA); Rutgers University

Active, not recruiting

Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Propranolol/Carvedilol Versus Atenolol/Bisoprolol/Sotalol

Hypertension

United States
Food and Drug Administration (FDA)
Spaulding Clinical Research LLC

Completed

Electrophysiological Effects of Potential QT Prolonging Drugs

Pharmacokinetics | Pharmacodynamics | Drug-induced QT Prolongation

United States
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID)

Active, not recruiting

Early ART to Limit Infection and Establishment of Reservoir (EARLIER)

HIV-1 Infection

United States, Brazil, Malawi, Zimbabwe, Thailand, Peru
Pyramid Biosciences

Completed

A Study of PBI-200 With Ritonavir or Cobicistat in Healthy Volunteers

Drug-drug Interaction

United States
Bristol-Myers Squibb

Completed

A Study to Compare the Drug Levels of Atazanavir and Cobicistat Between the Coadministration of Age-Appropriate Mini-Tablet Formulations and the Coadministration of the Individual Reference Products in Healthy Adults Under Fed Conditions

Healthy Participants

United States
Janssen Research & Development, LLC

Completed

A Study of Darunavir in the Presence of Cobicistat When Administered as a Fixed Dose Combination Compared to the Co-administration of the Separate Available Formulations of Darunavir and Cobicistat Under Fed Conditions in Healthy Participants

Healthy

Belgium
Fred Hutchinson Cancer Center
National Institute on Drug Abuse (NIDA); Asociación Civil Impacta Salud y Educación... and other collaborators

Completed

HIV Test and Treat to Prevent HIV Transmission Among MSM and Transgender Women (SABES?)

HIV

Peru
Janssen Sciences Ireland UC

Completed

A Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Fixed Dose Combination (FDC) Versus a Regimen Consisting of Darunavir/Cobicistat FDC With Emtricitabine/Tenofovir Disoproxil Fumarate FDC in Treatment-naive HIV Type 1 Infected Subjects

Immunodeficiency Virus Type 1, Human

United States, France, Poland, United Kingdom, Belgium, Germany, Spain, Canada, Russian Federation, Puerto Rico
Academisch Ziekenhuis Maastricht
The Netherlands Cancer Institute; ZonMw: The Netherlands Organisation for Health...

Completed

Pharmacokinetic Boosting of Osimertinib (OSIBOOST)

Non Small Cell Lung Cancer

Netherlands
Hamad Medical Corporation

Completed

Darunavir/Cobicistat vs. Lopinavir/Ritonavir in COVID-19 Pneumonia in Qatar (DOLCI)

Pneumonia | COVID | Coronavirus

Qatar
Janssen Research & Development, LLC

Completed

A Study in Healthy Participants to Assess the Effect of Darunavir, Emtricitabine, and Tenofovir Alafenamide in the Presence of Cobicistat as Fixed Dose Combination (Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide) Compared With Co-administration of the Separate Agents

Healthy

Netherlands
National Institute of Allergy and Infectious Diseases...
Eunice Kennedy Shriver National Institute of Child Health and Human Development...

Completed

Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy

HIV Infections

United States, Puerto Rico, Thailand, Botswana, Argentina, Brazil, Tanzania, South Africa
Janssen Research & Development, LLC

Completed

A Study of Darunavir in the Presence of Cobicistat When Administered as a Fixed Dose Combination Under Fed Conditions

Healthy

Belgium
Fundacion SEIMC-GESIDA
Janssen-Cilag, S.A.

Completed

A Clinical Trial to Evaluate the Reversibility of Abacavir/Lamivudine/Dolutegravir CNS-Related Neurotoxicity After Switching to Tenofovir/Alafenamide/Emtricitabine/Darunavir/Cobicistat (TAF/FTC/DRV/c) (DETOX)

HIV Infections

Spain
National Institutes of Health Clinical Center (CC)

Completed

Impact of Once-Weekly Rifapentine and Isoniazid on the Steady State Pharmacokinetics of Dolutegravir and Darunavir Boosted With Cobicistat in Healthy Volunteers

HIV Infected Population With Latent Tuberculosis

United States
Fundación FLS de Lucha Contra el Sida, las Enfermedades...
ViiV Healthcare

Completed

EFFICACY AND SAFETY OF A SIMPLIFICATION STRATEGY BASED ON DOLUTEGRAVIR AND DARUNAVIR / COBICISTAT VS OPTIMIZED TREATMENT IN SUPPRESSED HIV-1-INFECTED PATIENTS CARRYING ARCHIVED MULTIDRUG RESISTANCE MUTATIONS

HIV-1 Infection

Spain
Sabyasachi Sen

Completed

Effect on HIV Medications on EPC Cells

AIDS

United States
Bristol-Myers Squibb

Completed

Taste Properties of Atazanavir and Cobicistat

HIV in Adults

United States
ANRS, Emerging Infectious Diseases
Institut National de la Santé Et de la Recherche Médicale, France

Completed

National Multicenter Trial Evaluating Two Treatments in Patients With Primary Human Immunodeficiency Virus (HIV-1) Infection (OPTIPRIM-2)

HIV-1 Infection

France
Janssen R&D Ireland

Completed

Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Regimen Versus Boosted Protease Inhibitor (bPI) Along With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) Regimen in Virologically-Suppressed, HIV-1 Infected Participants

Human Immunodeficiency Virus Type 1

United States, France, United Kingdom, Belgium, Spain, Switzerland, Sweden, Canada, Puerto Rico, Poland
Bristol-Myers Squibb

Completed

A Study to Examine the Acceptable Taste and to Estimate the Amount of Atazanavir and Cobicistat in the Body When Taken as a Combination Product Versus When Taken as Separate Products at the Same Time

Healthy Participants

United States
Johns Hopkins University
Gilead Sciences

Completed

Analysis of Crushed and Whole Tablet Genvoya

Healthy Volunteers

United States
Hospitales Universitarios Virgen del Rocío
Instituto de Salud Carlos III

Completed

Tripe Versus Dual Antiretroviral Therapy in HIV-infected Patients With Virological Suppression (Tridual) (Tridual)

HIV Infections

Spain
Emory University
Centers for Disease Control and Prevention

Completed

Body Compartment Pharmacokinetics of Anti-retroviral Agents That May be Considered for Future On-demand Peri-exposure HIV Prophylaxis Regimens

HIV/AIDS

United States
Stanford University
University of Colorado, Denver; Janssen Scientific Affairs, LLC

Withdrawn

Darunavir/Cobicistat and Dolutegravir to Maintain Virologic Suppression and Reduce NRTI-associated Toxicity (TMC114HIV2030)

HIV/AIDS

United States
Janssen Pharmaceutica N.V., Belgium

Completed

Study to Assess the Acceptability of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Fixed-Dose Combination (FDC) Tablets in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Pediatric Participants, Using Matching Placebo Tablets

HIV-1

United States, Spain

3

Subscribe